PDS Biotechnology to Present at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference

PRINCETON, N.J., Feb. 17, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer and Dr. Lauren Wood, Chief Medical Officer are scheduled to participate in Noble Capital Markets' 16^th Annual Small & Microcap Investor Conference being held on February 16-18, 2020 at the Seminole Hard Rock Hotel & Casino in Hollywood, FL.

Details of the presentation are as follows:

Panel Discussion: Cancer Treatment: Tackling the Disease Through Innovative Strategies
Date: Monday, February 17, 2020
Time: 5:30pm ET
Presenter: Dr. Lauren Wood
Location: Seminole Hard Rock Hotel & Casino, Terrace Ballroom C

Presentation: PDS Biotechnology Corporate Presentation
Date: Tuesday, February 18, 2020
Time: 12:00pm ET
Presenter: Dr. Frank Bedu-Addo
Location: Seminole Hard Rock Hotel & Casino, Terrace Ballroom A

A live webcast of the corporate presentation may be accessed on the Company's website at pdsbiotech.com or directly here.

About PDS Biotechnology

PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune T-cell activating technology platform. The Versamune platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent tumor-specific killer T-cells. Using Versamune, PDS Biotech is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotech’s pipeline combines the Versamune technology with tumor-specific antigens across several cancer types. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101

PDS Biotech’s lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck, PDS Biotech is advancing a combination of PDS0101 and KEYTRUDA to a Phase 2 study in first line treatment of recurrent or metastatic head and neck cancer. In partnership with the National Cancer Institute (NCI), PDS Biotech is also advancing a combination of PDS0101 and two clinical stage immunotherapies to a Phase 2 study in advanced HPV-associated cancers. A third phase 2 study is to be performed in advanced localized cervical cancer combining PDS0101 with the chemoradiotherapy, which is the standard of care.